Todos os posts
Revisão sistemática | Oxicodona para dor relacionada a câncer.
19 Jun, 2022 | 13:05hOxycodone for cancer‐related pain – Cochrane Library
Resumo: Oxycodone for cancer-related pain in adults – Cochrane Library
DNA circulante de tumor e recorrência tardia em câncer de mama de alto risco, positivo para receptor de hormônio e negativo para receptor do fator de crescimento epidérmico humano 2.
19 Jun, 2022 | 13:04hComentário: Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in Advance — First evidence for patients in late adjuvant setting, years after initial diagnosis – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter
103 women in long-term remission from high-risk HR+/HER2- breast cancer had customized monitoring of recurrence based on ctDNA seq for tumour-associated mut. Among 8 pts MRD+ pts, 6 developed distant recurrence at a median 12.4 mo after ctDNA positivity https://t.co/aX1ruLCSbb
— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022
Seguimento de 2 anos de estudo de braço único | Ciltacabtageno Autoleucel, uma terapia de células T do receptor de antígeno quimérico anticélula B de maturação, para mieloma múltiplo recorrente/refratário.
19 Jun, 2022 | 13:02hEstudo original: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link para o resumo – $ para o texto completo)
Comentário no Twitter
In follow-up from CARTITUDE-1 trial of ciltacabtagene autoleucel in R/R MM, ORR was 97.9% and 82.5% had a stringent CR. 27-mo PFS was 54% and OS was 70.4% https://t.co/cnpzkg5yKM
— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022
Estudo de coorte retrospectiva | Incidência de eventos cardíacos adversos maiores com imunoterápicos.
19 Jun, 2022 | 13:00hConteúdos relacionados:
Cardiotoxicity of immune checkpoint inhibitors – ESMO Open
Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature
Seguimento de longo prazo de estudo randomizado | Craniectomia descompressiva vs. cuidado médico padrão para pacientes com hipertensão intracraniana traumática.
16 Jun, 2022 | 14:03hEvaluation of Outcomes Among Patients With Traumatic Intracranial Hypertension Treated With Decompressive Craniectomy vs Standard Medical Care at 24 Months: A Secondary Analysis of the RESCUEicp Randomized Clinical Trial – JAMA Neurology (gratuito por tempo limitado)
Estudo original: Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension – New England Journal of Medicine
Conteúdos relacionados:
The Current Status of Decompressive Craniectomy in Traumatic Brain Injury – Current Trauma Reports
Comentário no Twitter
In this study, at 24 months, patients with posttraumatic refractory intracranial hypertension managed with a decompressive craniectomy had a sustained mortality reduction and higher rates of vegetative state, severe disability, and moderate disability. https://t.co/I8GqG885jh
— JAMA Neurology (@JAMANeuro) June 9, 2022
Outro estudo sugere que a variante Ômicron está associada com risco reduzido de síndrome inflamatória multissistêmica em crianças em comparação a variantes anteriores do SARS-CoV-2.
16 Jun, 2022 | 14:01hEstudo relacionado: Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel – JAMA E Commentary: Kids’ COVID syndrome—MIS-C—less severe in Omicron – CIDRAP
Comentário no Twitter
Study found that the risk of multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection during the #Omicron wave substantially lower compared to previous #SARSCoV2 variants. https://t.co/GYrz9XA72Z
— JAMA Pediatrics (@JAMAPediatrics) June 8, 2022
Estudo randomizado | Suplementação de ácido graxo ômega 3 de origem marinha não reduz a incidência de olho seco em adultos saudáveis.
16 Jun, 2022 | 14:00hEfficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults: A Randomized Clinical Trial – JAMA Ophthalmology (gratuito por tempo limitado)
Comentário convidado: Another Disappointment for ω-3 Fatty Acid and Dry Eye Disease – JAMA Ophthalmology (gratuito por tempo limitado)
Comentário no Twitter
In this randomized clinical trial, daily supplementation with marine omega-3 fatty acids (1 gram) for a median of 5.3 years had no significant effect on the incidence of diagnosed #dryeyedisease (DED) or reported DED symptoms. https://t.co/iTBONh6CZK
— JAMAOphthalmology (@JAMAOphth) June 9, 2022
Estudo de coorte | Desfechos de neurodesenvolvimento em 1 ano em bebês de mães com teste positivo para SARS-CoV-2 durante a gestação.
16 Jun, 2022 | 13:58hComentários:
Comentário no Twitter
This cohort study of #SARSCoV2 exposure in utero found preliminary evidence that maternal SARS-CoV-2 may be associated with neurodevelopmental sequelae in some offspring. https://t.co/dYdoJbNOdl
— JAMA Network Open (@JAMANetworkOpen) June 9, 2022
Revisão | O impacto e os riscos do surgimento de complicações do diabetes melito.
16 Jun, 2022 | 13:56hThe burden and risks of emerging complications of diabetes mellitus – Nature Reviews Endocrinology
Comentário no Twitter
New content online: The burden and risks of emerging complications of diabetes mellitus https://t.co/mWcYa7TsKz
— Nature Reviews Endocrinology (@NatureRevEndo) June 6, 2022